São Paulo, October 8, 2025 – Eurofarma has begun operations at its new plant in Montes Claros (MG), the company’s largest industrial complex and one of the biggest in the pharmaceutical sector across the Southern Hemisphere. The new facility strengthens the company’s strategy to stay on a path of growth and international expansion. In addition to substantially increasing Eurofarma’s manufacturing capacity, it also brings social investments to the municipality and a proposal for positive environmental impact, aiming to balance the sustainability triple bottom line by combining economic and socio-environmental aspects—an undertaking expected to support the organization’s growth in Brazil and abroad for decades to come.

“Montes Claros is a milestone for our company’s future. We are bringing cutting-edge technology to a state-of-the-art plant, creating jobs and offering development opportunities. We expect to at least double our global production once all phases of the operation are completed. In 2024, our manufacturing exceeded 600 million units. With the contribution of the new plant, we intend to further expand our portfolio and production to ensure greater product availability, broader access, and to seize all market opportunities,” says Roberta Costa, Vice President of Operations at Eurofarma Group.

“The investment in this project and its magnitude reflect the ambition, growth, and geographic expansion outlined in our long-term strategic plan. With sustainable practices, direct social impact, and cutting-edge technology, we are targeting gains in scale, eco-efficiency, and international certifications. This is a fundamental step that prepares the company for future challenges and opportunities—an expression of our Vision 2072, which aims to position Eurofarma in the world’s leading pharmaceutical markets so we can become increasingly global,” comments Maria del Pilar Muñoz, Vice President of Sustainability and New Business at Eurofarma Group.

With a total area of 515,000 m² and approximately 250,000 m² of built area, the complex was designed in modules, enabling phased expansions over the next decade. At full capacity, it is expected to generate more than 2,000 direct jobs and up to 1,000 indirect jobs, consolidating the municipality as one of the main pharmaceutical industry hubs. During the construction phase, the project already mobilized more than 1,500 workers and dozens of local suppliers, demonstrating an immediate multiplier effect on the economy.

The plant will be able to produce different pharmaceutical dosage forms across a wide range of therapeutic classes. The first lines to begin operations will be packaging, with gradual expansion toward drug manufacturing. The choice of Montes Claros is related to the municipality’s strategic geographic location, connecting Brazil’s Southeast and Northeast regions, improving national logistics and creating competitive conditions for exports. The city, which has already attracted other pharmaceutical investments, has been consolidating itself as a growing industrial hub.

The project was developed in line with Eurofarma’s growth plans and environmental commitments. In 2024, the company reached 90% use of clean energy in its global operations and neutralized 85% of its direct emissions. Designed to operate with modern, efficient processes that are less intensive in natural resources, the new unit is expected to contribute positively to the eco-efficiency indicators that distinguish the company in the sector.

The social impact of the new operation goes far beyond local hiring. The Eurofarma Institute, which over 20 years has benefited more than 180,000 young people through education and workforce training programs, celebrated the first graduating class in Montes Claros even before the new operation began, training 30 nursing technicians. In addition, the company has supported the local health department with donations of medicines to reduce public costs and expand access for the population.

About Eurofarma
Founded in 1972, Eurofarma operates in the healthcare sector through the production and commercialization of products and services to improve people’s quality of life. Focused on generating shared value, it covers the main pharmaceutical segments, such as prescription medicines, generics, hospital, oncology, OTC, personal care, and animal health, in addition to providing third-party manufacturing services. With broad coverage across therapeutic classes, the portfolio includes more than 4,000 SKUs, serving virtually all medical specialties. A leader in medical prescriptions in Brazil—where it also holds the #2 position in generics—Eurofarma is present in 24 countries, with full coverage across Latin America and leadership in the region’s retail market. It also maintains operations in the U.S. and Africa, employing more than 13,500 people and operating 11 plants. The company produced 600 million units in 2024. That same year, it invested more than R$ 800 million in innovation projects and achieved net revenue exceeding R$ 11 billion.

Press Information
G&A Relações Públicas
Email: imprensaeurofarma@gaspar.com.br
Iza França – +55 11 97644-4496 (iza.franca@gaspar.com.br)
Guilherme Gaspar – +55 11 98285-6000